Browse News
Filter News
Found 17,693 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
3/28/2024
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
-
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
3/28/2024
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced leadership from its business verticals will be presenting at, and participating in, the following conferences.
-
Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033
3/28/2024
The global cell and gene therapy CDMO Market size was valued at USD 5.90 billion in 2023 and is projected to reach USD 69.11 billion by 2033,
-
Advanced Therapy Medicinal Products CDMO Industry is Rising Rapidly
3/28/2024
According to latest study, the global advanced therapy medicinal products CDMO Market size was valued at USD 6.10 billion in 2023 and is projected to reach USD 34.53 billion by 2033
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
Genetic Analysis Market Size to Attain Around USD 23.60 BN by 2033
3/28/2024
The global genetic analysis market was evaluated at USD 10.55 billion in 2023 and is expected to attain around USD 23.60 billion by 2033
-
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
3/28/2024
INmune Bio Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces its financial results for the year ended December 31, 2023 and provides a business update.
-
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
3/28/2024
Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision
-
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
3/28/2024
Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023.
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
3/28/2024
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.
-
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
3/28/2024
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
-
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
3/28/2024
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
-
Vertex and CRISPR Therapeutics are setting up treatment centers for patients with beta thalassemia and sickle cell disease to compete with bluebird’s established infrastructure.
-
Nanoscope Therapeutics nabbed a victory on the changed primary endpoint of its Phase IIb vision loss gene therapy trial Tuesday, teeing the biotech up to file for FDA approval of the candidate this year.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Coave Therapeutics to Present at Upcoming Conferences - March 27, 2024
3/27/2024
Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Xcell Biosciences Announces New Scientific and Business Advisory Board
3/27/2024
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.